

**Supplementary Table 1.**

Case-control and cohort studies addressing the relationship between HBV and CKD  
(outcome: frequency of end-stage renal disease or chronic kidney disease) (clinical characteristics)

\*Numbers are reported as HBsAg positive/HBsAg negative patients, respectively

\*\*Numbers are reported as untreated/uninfected patients, respectively

|                             | Follow-up,<br>mo                            | Anti-HCV<br>positive, <i>n</i> | HBsAg rate, <i>n</i>      | Age,<br>yrs                               |
|-----------------------------|---|--------------------------------|---------------------------|---|
| <b>Case-control studies</b> |   |                                |                           |   |
| Chen Y, <i>et al.</i>       | 6.5   | 0                              | 20.0%<br>(17,796/88,980)  | NA  |
| Su S, <i>et al.</i>         | NA  | 1.6%<br>(169/10,463)           | 3.6%<br>(371/10,463)      | 59.8 <sub>+1</sub> /54 <sub>+1</sub> *    |
| Kim S, <i>et al.</i>        | 0   | 0                              | 20.0%<br>(10,048/50,240)  | 49.5 <sub>+9</sub> /49.4 <sub>+9</sub>    |
| Nguyen M, <i>et al.</i>     | NA  | 2.8%<br>(1,221/43,482)         | 26.5%<br>(44,026/165,594) | NA  |
| <b>Cohort studies</b>       |   |                                |                           |   |
| Lo M, <i>et al.</i>         | 1.99 (0.06-4.12)                            | NA                             | 15.4% (15/97)             | 62.3 <sub>+6.4</sub>                      |
| Cheng A, <i>et al.</i>      | 3.5 yrs                                     | NA                             | 10.1% (286/2,838)         | 59.7 <sub>+12.9</sub>                     |
| Chen Y, <i>et al.</i>       | 6.5 yrs                                     | 0                              | 20.0%<br>(17,758/88,790)  | NA  |
| Lee J, <i>et al.</i>        | 2.2 <sub>+1.6</sub>                         | 6.5% (317/4,185)               | 7.4% (309/4,185)          | 61.9 <sub>+14.8</sub>                     |
| Kong X, <i>et al.</i>       | 5 yrs                                       | 0                              | 8.1% (352/4,329)          | 46.2 <sub>+13.7</sub>                     |
| Hwang J, <i>et al.</i>      | 3.9 <sub>+3.06</sub>                        | 50.0%<br>(9,787/19,574)        | 5.4%<br>(1,072/19,574)    | 55.7 <sub>+1</sub>                        |
| Chen Y, <i>et al.</i>       | 8.9 <sub>+3.9</sub> /7.4 <sub>+4.5</sub> ** | 0                              | 20.0%<br>(2,916/14,580)   | 48.1 <sub>+1</sub> /47.7 <sub>+1</sub> ** |
| Si J, <i>et al.</i>         | 9.1 yrs                                     | NA                             | 3.1%<br>(14,871/469,459)  | 48.6/51.1*                                |
| Hong Y, <i>et al.</i>       | 5.6 yrs                                     | 0                              | 3.9%<br>(11,209/299,913)  | 37.3 <sub>+7.9</sub>                      |
| Fang J, <i>et al.</i>       | 25<br>(2-61) mo                             | 0                              | 9.0%<br>(16/177)          | 32 (19-62)                                |
| Tartof S, <i>et al.</i>     | 3.8 <sub>+2.9</sub>                         | 1.0%<br>(1,534/152,708)        | 0.3%<br>(483/153,577)     | 72 (64-80)                                |

**Supplementary Table 2.**

Case-control and cohort studies addressing the relationship between HBV and CKD  
(outcome: frequency of end-stage renal disease or chronic kidney disease) (clinical characteristics)

|                             | <b>Male,<br/><i>n</i></b>  | <b>Diabetes<br/>mellitus, <i>n</i></b> | <b>Hypertension,<br/><i>n</i></b> | <b>Cirrhosis,<br/><i>N</i></b> |
|-----------------------------|----------------------------|--|-----------------------------------|--------------------------------|
| <b>Case-control studies</b> |                            |  |                                   |                                |
| Chen Y, <i>et al.</i>       | 58.5%<br>(52,140/88,980)   | 7.7%<br>(6,841/88,980)                 | 12.9%<br>(11,531/88,980)          | 1.2%<br>(1,104/88,980)         |
| Su S, <i>et al.</i>         | 37.2%<br>(3,893/10,463)    | 30.4%<br>(3,182/10,463)                | 55.4%<br>(5,656/10,463)           | NA                             |
| Kim S, <i>et al.</i>        | 64.4%<br>(32,355/50,240)   | NA                                     | NA                                | NA                             |
| Nguyen M, <i>et al.</i>     | NA                         | 15.8%<br>(6,873/43,482)                | 36.1%<br>(15,740/43,482)          | NA                             |
| <b>Cohort studies</b>       |                            |  |                                   |                                |
| Lo M, <i>et al.</i>         | 63.4% (59/93)              | 100.0% (97/97)                         | NA                                | NA                             |
| Cheng A, <i>et al.</i>      | 41.1%<br>(1,169/2,838)     | 100.0%<br>(2,838/2,838)                | NA                                | NA                             |
| Chen Y, <i>et al.</i>       | 58.5%<br>(51,990/88,790)   | 7.9%<br>(7,062/88,790)                 | 13.5%<br>(12,035/88,790)          | 1.2%<br>(1,100/88,790)         |
| Lee J, <i>et al.</i>        | 58.4%<br>(2,447/4,185)     | 39.9%<br>(1,673/4,185)                 | 61.0%<br>(2,553/4,185)            | 4.5%<br>(177/4,185)            |
| Kong X, <i>et al.</i>       | 67.2%<br>(2,907/4,329)     | 10.5%<br>(454/4,329)                   | 21.4%<br>(927/4,329)              | NA                             |
| Hwang J, <i>et al.</i>      | 51.3%<br>(10,044/19,574)   | 100.0%<br>(19,574/19,574)              | 39.1%<br>(7,659/19,574)           | 5.7%<br>(1,114/19,574)         |
| Chen Y, <i>et al.</i>       | 58.1%<br>(8,475/14,580)    | 26.0%<br>(3,798/14,580)                | 29.5%<br>(4,304/14,580)           | 4.1%<br>(611/14,580)           |
| Si J, <i>et al.</i>         | 40.9%<br>(192,445/469,459) | 5.4%<br>(25,395/469,459)               | 33.8%<br>(158,908/469,459)        | 1.2%<br>(5,682/469,459)        |
| Hong Y, <i>et al.</i>       | 56.7%<br>(170,050/299,913) | 2.4%<br>(7,198/299,913)                | 11.7%<br>(35,089/299,913)         | NA                             |
| Fang J, <i>et al.</i>       | 17.5% (31/177)             | NA                                     | NA                                | NA                             |
| Tartof S, <i>et al.</i>     | 45.9%<br>(70,527/153,577)  | 31.7%<br>(48,735/153,577)              | 61.1%<br>(93,885/153,577)         | 1.2%<br>(1,948/153,577)        |